Company Overview and News
It has been a good year for local equities. In fact we're not far from being able to call it a good decade with the NZX bull-run moving into its ninth year in 2018. (4-1)
Questions are being raised about whether Orion Health will need to raise more cash after its poor half-year result. (2-0)
New Zealand shares gained, with Fletcher Building rising as investors were lured back after its recent weakness, while Orion Health Group hit a record low. (15-0)
Pacific Edge's share price tumbled 27.7 per cent this week, from 47c to 34c, after it announced a fully underwritten 1-for-6 rights issue at 32c a share that will raise $21.3 million.
New Zealand shares rose as the export-orientated growth stocks A2 Milk and Xero extended recent gains, while insurer CBL Corp declined. (5-0)
Cellmid Limited (ASX:CDY) has had results from a melanoma study related to midkine published by the prestigious and renowned journal, Nature.
New Zealand shares edged higher on relatively small volumes as investors were preoccupied with the government's budget and a slew of earnings, including Metro Performance Glass, which reported a boost in sales on its Australian expansion.
Arvida Group led the New Zealand share market higher as investors were cheered by positive earnings reports and - like much of Asia - shrugged off news Moody's Investors Service cut its sovereign credit rating on China.
Cellmid (ASX:CDY) has achieved record sales of $1.51 million for the March quarter, up 120% from the same period last year.
DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the prestigious international journal, Urologic Oncology. The peer reviewed scientific and clinical paper validates the superior performance of Pacific Edge's Cxbladder Monitor test for the surveillance of patients who are being managed for recurrence following treatment for bladder cancer, compared to existing alternatives.
New Zealand shares rose, led by Sky Network Television and Westpac Banking Corp, while Tegel Group Holdings and A2 Milk Co dropped.
Cancer diagnostics company Pacific Edge has undertaken an $8 million share placement to institutional and other select investors in New Zealand in order to shore up its balance sheet.
Some undervalued "blue chip" companies and a selection of small cap stocks dominate our broker picks for the year ahead.
DUNEDIN, New Zealand and HERSHEY, Pa., Dec. 12, 2016 /PRNewswire/ -- Pacific Edge Limited (NZX:PEB) ("Pacific Edge"), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announced today the commercial launch of the third product in the Company's Cxbladder family of products, Cxbladder Monitor, in the United States.
Cellmid (ASX:CDY) to date has derived over $1.2 million from the midkine diagnostics license it issued to New Zealand based Pacific Edge in 2010.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton